Paul CPA - Fulgent Genetics Chief Officer
| FLGT Stock | USD 16.95 0.33 1.91% |
Executive
Paul CPA is Chief Officer of Fulgent Genetics
| Age | 57 |
| Address | 4399 Santa Anita Avenue, El Monte, CA, United States, 91731 |
| Phone | 626 350 0537 |
| Web | https://www.fulgentgenetics.com |
Fulgent Genetics Management Efficiency
The company has return on total asset (ROA) of (0.0415) % which means that it has lost $0.0415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1435) %, meaning that it created substantial loss on money invested by shareholders. Fulgent Genetics' management efficiency ratios could be used to measure how well Fulgent Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.16 in 2024. Return On Capital Employed is likely to drop to -0.07 in 2024. At this time, Fulgent Genetics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 30.5 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 49.4 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Yvonne Mackie | Agilent Technologies | N/A | |
| Philip Binns | Agilent Technologies | N/A | |
| Jakob Wedel | Illumina | N/A | |
| William IV | Danaher | 56 | |
| Ian Cooney | Caredx Inc | N/A | |
| Aaron Bloomer | EXACT Sciences | 38 | |
| Sheetal Parmar | Natera Inc | N/A | |
| Chet Gandhi | Twist Bioscience Corp | N/A | |
| Steven Barnard | Illumina | N/A | |
| Daniel LLM | Natera Inc | 55 | |
| Pat Leckman | Illumina | 60 | |
| Elena Markwalder | Mettler Toledo International | N/A | |
| Michael Esq | Thermo Fisher Scientific | 62 | |
| Nassar Nizami | EXACT Sciences | N/A | |
| Pr Frearson | Charles River Laboratories | N/A | |
| Marco Scheller | Caredx Inc | N/A | |
| Anu MS | Natera Inc | N/A | |
| Ryan Snyder | Thermo Fisher Scientific | N/A | |
| Jerry Diffley | Natera Inc | N/A | |
| Sharon Vidal | Illumina | N/A | |
| Jessica Meng | Caredx Inc | N/A | |
Management Performance
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0415 |
Fulgent Genetics Leadership Team
Elected by the shareholders, the Fulgent Genetics' board of directors comprises two types of representatives: Fulgent Genetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fulgent. The board's role is to monitor Fulgent Genetics' management team and ensure that shareholders' interests are well served. Fulgent Genetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fulgent Genetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Doreen Ng, VP Office | ||
| DABMG FACMG, Chief Director | ||
| Paul Kim, Chief Officer | ||
| Ming Hsieh, Chairman of the Board and Presidentident, CEO | ||
| Natalie Prescott, General Officer | ||
| Lawrence MD, Chief Officer | ||
| Ray Yin, President Pharma | ||
| Brandon Perthuis, Chief Officer | ||
| Jian Xie, COO President | ||
| Ellen Tsui, Vice Resources | ||
| Jakub Sram, Vice Sales | ||
| Paul CPA, Chief Officer |
Fulgent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fulgent Genetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0415 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 314.43 M | ||||
| Shares Outstanding | 30.59 M | ||||
| Shares Owned By Insiders | 32.33 % | ||||
| Shares Owned By Institutions | 54.22 % | ||||
| Number Of Shares Shorted | 645.62 K | ||||
| Price To Earning | 3.95 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.